Most Recent
Pfizer has lost a patent infringement lawsuit against Samsung Bioepis over the generic version of its blockbuster autoimmune drug Enbrel, with a judge finding all but one of the patent's claims is invalid.
Aristocrat has taken gaming giant Konami to court, alleging that more than 50 of the Japanese company's casino games infringe its patents.
Acciona is mulling a bid to summarily dismiss a "hopelessly flawed" patent suit by its construction partner on the troubled East Rockingham waste-to-energy plant project, saying it is doomed in light of a High Court decision holding a patentee’s rights are exhausted at the time of sale.
The High Court has been asked to clarify the extent to which computer-implemented ideas are eligible for patent protection, with IP Australia appealing a win for gaming giant Aristocrat.
It faced defeat at the Full Federal Court and encountered a deadlocked High Court, still Aristocrat persisted in its seven-year fight to get patent protection for the popular Lightning Link poker machine. The long game paid off.
Drug giant Sanofi has failed in its appeal of a decision granting applications by biopharmaceutical company Amgen for patents covering the cholesterol-lowering treatment Repatha.
The High Court won't hear Bayer's appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company's claim the decision has "profound" consequences for drug R&D.
The High Court has rejected Aristocrat's request that it rule again on the patentability of its popular Lightning Link game, after a differently comprised court was split on when computer-implemented inventions can be patented.
Bayer has filed a High Court challenge to a decision that invalidated its patents for blockbuster blood thinner Xarelto, saying it would adversely affect drug research and development.
Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.